modelMacrogolCombinations
Extends from Pharmacolibrary.Drugs.ATC.A.A06AD65.
Information
| name: | MacrogolCombinations | |
| ATC code: | A06AD65 | route: | oral |
| compartments: | 1 | |
| dosage: | 17000 | mg |
| volume of distribution: | 9 | L |
| clearance: | 0.5 | L/h |
| other parameters in model implementation | ||
Macrogol (also known as polyethylene glycol) combinations are used primarily as osmotic laxatives to treat constipation and to facilitate bowel cleansing before diagnostic procedures such as colonoscopy. Macrogol is widely used and approved for these indications in many countries.
Pharmacokinetics
Pharmacokinetic parameters for macrogol combinations in healthy adult volunteers following oral administration.
References
Hruska, MW, et al., & Marsteller, DA (2024). Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving Opioids. Clinical pharmacology in drug development 13(9) 974–984. DOI:10.1002/cpdd.1457 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39110083
Keating, GM, & Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63(7) 701–730. DOI:10.2165/00003495-200363070-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12656650
Xu, C, et al., & Sniukiene, V (2013). Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. European journal of clinical pharmacology 69(12) 2045–2054. DOI:10.1007/s00228-013-1574-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23975236
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)